Galapagos NV initiates ISABELA Phase 3 program

Galapagos NV announced that it has dosed its first patient in the worldwide ISABELA Phase 3 program with autotaxin inhibitor GLPG1690 in IPF. “Today’s news again demonstrates our commitment to the rapid advancement of our IPF franchise, including the ISABELA and the PINTA trials. We are excited by the feedback received from participating sites and KOLs, which underscores the need for novel treatments to address the remaining high unmet need in IPF,” said Galapagos Chief Medical Officer Dr. Walid Abi-Saab.
https://thefly.com/landingPageNews.php?id=2838237